medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 09

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (09)

Therapeutic vaccines of the human papilloma virus: current evidence review

Fernández GI, Cristóbal I, Neyro JL

Language: Spanish
References: 29
Page: 615-624
PDF size: 271.05 Kb.


ABSTRACT

Objective: To assess the immunogenicity of different types of therapeutic vaccines and their effect on human papillomavirus (HPV) lesions after application. In addition, to analyze the safety studies and prospects of therapeutic HPV vaccines.
Methodology:METHODOLOGY: Retrospective study based on a systematic literature search of the PubMed database, with no publication date restrictions. Inclusion criteria: randomized clinical trials (meta-analyses and systematic reviews). Exclusion criteria: clinical trials in the pre-clinical phase of development and publications in languages other than English or Spanish.
Results: 30 articles published between 2000 and 2020 were selected. Among them, 5 randomized clinical trials with therapeutic vaccines that have already been completed or are still under study. The remaining 25 publications include: meta-analyses and systematic reviews of selected aspects with primary and secondary objectives.
Conclusions: Therapeutic HPV vaccines are in the experimental phase; so far promising results have been achieved with some of them. Although different types of therapeutic vaccines exist, the best results have been achieved with DNA-based vaccines. The VGX-3100 and TS vaccines, in phase III, have demonstrated significant differences in viral clearance and regression of high-grade lesions in vaccinated patients. An effective therapeutic vaccine would have an immediate impact on morbidity and mortality from virus-associated lesions.


REFERENCES

  1. Münger K, et al. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89 (2): 213-28. https://doi.org/10.1016/S0168-1702(02)00190-9

  2. Richard BS, et al. Opportunities and challenges for human papillomavirus vaccination in cancer. Nature Reviews Cancer 2018; 18: 240-54. 10.1038/nrc.2018.13

  3. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6: 753-63. https://doi. org/10.1038/nrc1973

  4. Roden RB, Monie A, Wu TC. Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med 2007; 7: 490-503.

  5. Clark KT, Trimble CL. Current status of therapeutic HPV vaccines. Gynecol Oncol. 2020; 156 (2): 503-10. https:// doi.org/10.1016/j.ygyno.2019.12.017

  6. Schiller JT, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26 (Suppl 10): 53-61. https://doi. org/10.1016/j.vaccine.2008.06.002

  7. Hung CF, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008; 8: 421-39. https://doi. org/10.1517/14712598.8.4.421

  8. Vonsky MS, et al. Therapeutic vaccines against human papilloma viruses: Achievements and prospects. Biochemistry (Mosc) 2019; 84 (7): 800-16. https://doi.org/10.1134/ S0006297919070101

  9. Fausch SC, et al. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci 2003; 8: 81-91.

  10. Gerard CM, et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 2001; 19: 2583-89. https://doi.org/10.1016/S0264-410X(00)00486-2

  11. Yang A, et al. Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 2016; 15 (8): 989-1007. https://doi.org/10.1586/14760584.2016 .1157477

  12. Hung CF, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008; 8: 421-39. https://doi. org/10.1517/14712598.8.4.421

  13. Gurunathan S, et al. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927- 74. https://doi.org/10.1146/annurev.immunol.18.1.927

  14. Trimble C, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21: 4036-42. https://doi.org/10.1016/ S0264-410X(03)00275-5

  15. Best SR, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27: 5450-59. https://doi.org/10.1016/j.vaccine.2009.07.005

  16. Zeira E, et al. Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. Faseb J 2007; 21: 3522-33. https://doi.org/10.1096/fj.06-7528com

  17. Storrie H, Mooney DJ. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Deliv Rev 2006; 58: 500-14. https://doi.org/10.1016/j. addr.2006.03.004

  18. Yan J, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27: 431-40. https:// doi.org/10.1016/j.vaccine.2008.10.078

  19. Ohlschlager P, et al. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequenceoptimized genetic adjuvants. Int J Cancer 2009; 125: 189-98. https://doi.org/10.1002/ ijc.24333

  20. Mousavi T, et al. Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. Arch Virol. 2020; 165 (2): 263-84. https://doi.org/10.1007/s00705-019-04479-4

  21. Larange A, et al. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol 2009; 85: 673-83. https://doi.org/10.1189/ jlb.0808504

  22. Petrausch U, et al. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med 2009; 9: 673-82. https:// doi.org/10.2174/156652409788970670

  23. Special Report Policy. A review of humans carcinogens. Lancet 2009; 10: 1143-44.

  24. Trimble CL, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015; 386 (10008): 2078-88. https://doi.org/10.1016/ S0140-6736(15)00239-1

  25. Harper DM, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. Gynecologic Oncology 2019; 153 (3): 521-29. https://doi.org/10.1016/j. ygyno.2019.03.250

  26. Kim TJ, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nature communications 2014; 5: 5317. https://doi. org/10.1038/ncomms6317

  27. Lin K, et al. Therapeutic HPV DNA vaccines. Immunol Res. 2010; 47 (1-3): 86-112. doi10.1007/s12026-009-8141-6

  28. Hancock G, et al. Therapeutic HPV vaccines. Best Practice & Research Clinical Obstetrics and Gynaecology 2018; 47: 59-72. https://doi.org/10.1016/j.bpobgyn. 2017.09.008

  29. Wang R, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020; 471: 88-102. https://doi.org/10.1016/j.canlet. 2019.11.039




2020     |     www.medigraphic.com